ArticleInternational journal of nanomedicine2017
Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 284 citations in OpenAlex.
- Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review.International journal of nanomedicine · 2019Pooled it
- Advances and Hurdles of PLGA-Based Therapy for Pancreatic Cancer.AAPS PharmSciTech · 2026Review
- Engineering Cobalt Bis(dicarbollide)-Loaded Polymeric Nanocarriers: From Controlled Fabrication to Drug Delivery for BNCT.Journal of functional biomaterials · 2026Article
- Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Folic acid-targeted albumin nanoliposomes co-loaded with paclitaxel and doxorubicin for enhanced treatment of lung cancer.Scientific reports · 2026Article
- Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy.Materials today. Bio · 2026Article
- A novel Kupffer cell-targeting nanoparticle system to Mitigate alcohol-associated liver disease.Biomaterials · 2026Article
- Unfolding and Degradation of Micellar Immunodrug Carriers Derived From End Group Modified Aliphatic Poly(Carbonate)s with Acid-Responsive Ketal Side Groups.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Article
- Recent advances in extracellular matrix-inspired nanocarriers.Expert opinion on drug delivery · 2025Review
- Targeting Polymeric Nanoparticles to Specific Cell Populations in the Liver.Biochemistry · 2025Review
- Blood nerve barrier permeability enables nerve targeting of circulating nanoparticles in experimental autoimmune neuritis.Scientific reports · 2025Article
- Water-soluble fluorinated copolymers as highly sensitiveMaterials today. Bio · 2025Article
- Development of Polymeric Nanoparticles Loaded withInternational journal of molecular sciences · 2025Article
- How do nanoparticle properties shape pharmacokinetics and pharmacodynamics? A mechanistic review.Frontiers in pharmacology · 2025Review
- Mannosamine-Engineered Nanoparticles for Precision Rifapentine Delivery to Macrophages: Advancing Targeted Therapy Against Mycobacterium Tuberculosis.Drug design, development and therapy · 2025Article
- Research Progress of Docetaxel Nano-Drug Delivery System in the Treatment of Breast Cancer.International journal of nanomedicine · 2025Review
- Article
- Application of PLGA in Tumor Immunotherapy.Polymers · 2024Review
- Integrating osteoimmunology and nanoparticle-based drug delivery systems for enhanced fracture healing.Nanomedicine : nanotechnology, biology, and medicine · 2024Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Docetaxel is a highly potent anticancer agent being used in a wide spectrum of cancer types. There are important matters of concern regarding the drug's pharmacokinetics related to the conventional formulation. Poly(lactide-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.